Galmed Pharmaceuticals Ltd.EOCN
Price (close)
$3.62
Market cap
—
P/E
—
Revenue (FY)
—
Net income
-$10.3M
Dividend yield
—
1-year total return
-67.2%
Net margin
—
Revenue growth
—
Debt / equity
—
What Galmed Pharmaceuticals Ltd. does.
are a biopharmaceutical company focused on the development of Aramchol, a first-in-class, oral, SCD1 modulator. Historically, we have
focused almost exclusively on developing Aramchol for the treatment of liver diseases and were previously developing Aramchol for primary
sclerosing cholangitis, or PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — | — |
| Net income | -$28.8M | -$32.5M | -$17.9M | -$6.9M | -$7.5M | -$10.3M |
| Free cash flow | -$26.3M | -$32.9M | -$18.5M | — | — | — |
More on EOCN.
- Galmed Pharmaceuticals Ltd. summary
- Galmed Pharmaceuticals Ltd. financial statements
- Galmed Pharmaceuticals Ltd. key metrics
- Galmed Pharmaceuticals Ltd. health scores and style box
- Galmed Pharmaceuticals Ltd. earnings
- Galmed Pharmaceuticals Ltd. dividends
- Galmed Pharmaceuticals Ltd. valuation
- Galmed Pharmaceuticals Ltd. ownership and insiders
- Galmed Pharmaceuticals Ltd. peers
Figures from Galmed Pharmaceuticals Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.